晚期非小细胞肺癌中β-tubulin Ⅲ表达水平对化学治疗敏感性的影响  

Effect of beta-tubulin Ⅲ expression levels on chemotherapy sensitivity for advanced non-small cell lung cancer

作　　者：陈佳[1] 何松[1] 王淼舟[1] 郭燕[1] 张晓东[1] 吉志固[1] 朱亚芳[1] 陆俊国[1] 陶玉[1] 朱兴华[1] 王建红[1] 杨书云[1] 尹海兵[1] 谭清和[1] 

机构地区：[1]江苏省南通市肿瘤医院肿瘤内科,江苏南通226361

出　　处：《国际病理科学与临床杂志》2013年第1期37-41,共5页Journal of International Pathology and Clinical Medicine

基　　金：江苏省卫生厅面上项目(H200867)~~

摘　　要：目的:分析非小细胞肺癌(non-small cell lung cancer,NSCLC)患者β-tubulin Ⅲ的表达水平与化学治疗(化疗)敏感性的关系。方法:经病理确诊的晚期NSCLC患者以1:2随机分配至对照组和基因型组:对照组使用吉西他滨联合顺铂化疗;基因型组根据ERCC1及RRM1的表达情况进行个体化治疗。检测病理标本中β-tubulin Ⅲ的表达水平,比较β-tubulin Ⅲ蛋白表达水平与临床疗效之间的关系。结果:基因型组最终有118例NSCLC病例可评价,均可成功检测β-tubulin Ⅲ的表达情况。对照组有效率(37.5%)与基因型组有效率(47.5%)比较,差异无统计学意义(P>0.05)。基因型组中各组间有效率比较,差异无统计学意义(P>0.05);但β-tubulinⅢ低表达组有效率(55.1%)显著高于β-tubulin Ⅲ高表达组(36.7%,P<0.05)。结论:在晚期NSCLC腺癌亚型中,β-tubulin Ⅲ低表达患者疗效较好,β-tubulin Ⅲ高表达可能意味着对多西他赛耐药。Objective： To analyze the relation between β-tubulin Ⅲ expression level and chemosensitivity in non-small cell lung cancer （NSCLC）. Methods： The patients were divided into a control group and a genotype group with a proportion of 1：2. The control group received the treatment of gemcitabin and cisplatin, while the genotype group received individual therapy according to the level of ERCC 1 and RRM1. The correlation between β-tubulin Ⅲexpression level and chemosensitivity in NSCLC was analyzed. Results β-Tubulin Ill expression was detected in all patients in the genotype group. Compared with the genotype group （47.5%）, efficiency in the control group （37.5%） was not significantly different. Efficiency in patients with low expression of β-tubulin Ⅲ was significantly higher than that of patier.ts with high expression of β-tubulin Ⅲ （55.1% vs 36.7%, P〈0.05）. Conclusion： In advanced NSCLC subtypes, patients with low expression of β-tubulin Ⅲ have good therapeutic effect. High β-tubulin Ⅲ expression may indicate resistance to docetaxel.

关 键 词：非小细胞肺癌 Β-TUBULIN III ERCC1基因 RRM1基因 

分 类 号：R734.2[医药卫生—肿瘤]